European Brachytherapy Seeds Market Research Report
- Report Code: BR 1003
- Publish Date: Upcoming
The European brachytherapy seeds market, mainly driven by rapidly changing cancer treatment technology and growing number of cancer patients. The market was valued $68.8 million in 2013 and is expected to be $75.2 million by 2018, at a CAGR of 1.80%.
The report “Brachytherapy Seeds Market Forecast, 2012-2018", analyzes the market into segments such as Cesium-131, Iodine-125, Palladium-103, Iridium-192, and others. With a market value of $28.5 million and $19.5 million, Iodine-125 and Iridium-192 accounted 41.5% and 28.3% share, respectively in terms of the total internal beam radiotherapy devices market.
In Europe (Germany, France, Italy, Spain, and UK), the rising rates of cancer population have been driving the market growth. The market growth is significantly higher in North America because it is always inclined to the newer techniques while comparatively slow-moving markets such as Europe and Japan are maturing with both old and new technologies. North America is the most dynamic, highly competitive and the largest market for radiotherapy devices globally.
Currently, seed market is dominating the internal beam radiotherapy market. Internal Beam Radiotherapy market holds a minor share in the entire radiotherapy market and it is further shrinking due to non-supportive government reimbursement policy in the U.S. market. After the U.S. market, Europe and BRIC nations are the only potential markets to sustain this therapeutic procedure.
Prostate cancer is the model cancer for Brachytherapy. Other than skin cancer, prostate cancer is the most common cancer in American males. In 2011, there were an estimated 2,707,821 men living with prostate cancer in the United States. According to The American Cancer Society, in 2014, there will be 233,000 new cases of prostate cancer diagnosed and about 29,480 men will die of prostate cancer.
Prevalence of cancer worldwide has reached to 7.4 million (53%) in males and 6.7 million (47%) in females, with a ratio of 10:9. In 2012, there was an estimate of 14.1 million new cases of cancer in the world. In 2014, approximately 1,665,540 new cancer cases are diagnosed and 585,720 cancer deaths are registered in the US alone. Cancer remains the second most common cause of death in the US, accounting for nearly one of every four deaths.
The report also provides an extensive competitive landscaping of companies operating in this market. The key players of the market covered in this report are ELEKTA AB, Theragenics corp., C.R. Bard, Eckert & Ziegler BEBIG SA. The segment and country-specific company shares, news & deals, M&A, segment-specific pipeline products, product approvals and product recalls of the major companies is covered in the report.
Customization Options
Along with the market data, you can also customize MMM assessments that meet your company’s specific needs. Customize to get comprehensive industry standard and deep-dive analysis of the following parameters:
Product Analysis
- Usage pattern (in-depth trend analysis) of products (segment-wise)
- Product matrix which gives a detailed comparison of product portfolio of each company mapped at country and sub-segment level
- End-user adoption rate analysis of the products (segment and country wise)
- Comprehensive coverage of product approvals, pipeline products, and product recalls
Epidemiology Data
- Country-specific prevalence and patient pool of types of cancer such as prostate cancer, breast, cervical, penile, lungs, head and neck, and esophagus cancer.
- Disease progression (pattern analysis)
Procedure Volume Data
- Surgeries performed annually in each country tracked till sub-segment level of prostate cancer, breast, cervical, and head and neck cancer
Surgeon’s/Physician’s Perception Analysis
- Fast turn-around analysis of surgeon’s response to market events and trends
- Surgeon’s opinion about products from different companies
- Surgeon’s qualitative inputs on epidemiology data
Brand/Product Perception Matrix
- Comprehensive study of customers perception and behavior through our inbuilt social connect tool checking the virality and tonality of blogs
- Analysis of overall brand usage and familiarity and brand advocacy distribution (detractor/neutral/familiar)
Pricing Trends
- Cost Analysis of brachytherapy seeds in various countries.
- Procedural investment in major countries for prostate cancer, breast, cervical, and head and neck cancer
Please fill in the form below to receive a free copy of the Summary of this Report
Please visit http://www.micromarketmonitor.com/custom-research-services.html to specify your custom Research Requirement
| PRODUCT TITLE | PUBLISHED | |
|---|---|---|
|
|
North American Internal Beam Radiotherapy/Brachytherapy Market The North American Internal Beam Radiotherapy Market is mainly driven by rapidly changing Cancer treatment technology and Growing number of cancer patients.The Market was pegged at $241.7 million in 2013 and expected to be $252.6 million by 2018, growing at a CAGR of 0.9%. The Internal Beam Radiotherapy Market analyzes the market of devices by 3 segments such as Internal Beam Radiotherapy/Brachytherapy are Brachytherapy Seeds, Applicators & Afterloaders and Electronic Brachytherapy.The prominent players in the Radiotherapy Devices Market globally areElekta AB, Theragenics corp., C.R. Bard, Eckert & Ziegler BEBIG SA. |
Upcoming |
|
|
European Internal Beam Radiotherapy/Brachytherapy Market The European Internal Beam Radiotherapy Market is mainly driven by rapidly changing Cancer treatment technology and Growing number of cancer patients.The Market was pegged at $123.5 million in 2013 and expected to be $141.1 million by 2018, growing at a CAGR of 2.5%. The Internal Beam Radiotherapy Market analyzes the market of devices by 3 segments such as Brachytherapy Seeds, Applicators & Afterloaders and Electronic Brachytherapy.The prominent players in the Radiotherapy Devices Market globally areElekta AB, Theragenics corp., C.R. Bard, Eckert & Ziegler BEBIG SA. |
Upcoming |
|
|
Asian Internal Beam Radiotherapy/Brachytherapy Market The Asian Internal Beam Radiotherapy Market is mainly driven by rapidly changing Cancer treatment technology and Growing number of cancer patients.The Market was pegged at $68.2 million in 2013 and expected to be $90.6 million by 2018, growing at a CAGR of 5.8%. The Internal Beam Radiotherapy Market analyzes the market of devices by 3 segments such as Brachytherapy Seeds, Applicators & Afterloaders and Electronic Brachytherapy.The prominent players in the Radiotherapy Devices Market globally areElekta AB, Theragenics corp., C.R. Bard, Eckert & Ziegler BEBIG SA. |
Upcoming |
